Literature DB >> 16213153

Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study.

S Houterman1, M L G Janssen-Heijnen, A J M Hendrikx, H A van den Berg, J W W Coebergh.   

Abstract

This study investigates the independent influence of serious comorbidity and age on treatment and survival of prostate cancer patients diagnosed between 1995 and 2002 in the southern part of the Netherlands. Eight percent of patients<60 years had two or more concomitant diseases versus 27% of those aged 80 years or older. The number of patients undergoing radical prostatectomy or curative radiotherapy decreased significantly with increasing age. The proportion of patients aged 60-69 years undergoing prostatectomy decreased significantly from 32% of patients without comorbidity to 17% of patients with two or more comorbid conditions and from 8% to 3%, respectively, of those aged 70-79 years. The risk of dying was significantly higher for patients with two or more comorbid conditions compared to patients without comorbidity. Serious comorbidity led to less aggressive treatment and negatively affected the prognosis of prostate cancer patients aged 60-79 years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213153     DOI: 10.1016/j.critrevonc.2005.08.003

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  17 in total

1.  Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study.

Authors:  Melissa S Y Thong; Lonneke van de Poll-Franse; Richard M Hoffman; Peter C Albertsen; Ann S Hamilton; Janet L Stanford; David F Penson
Journal:  BJU Int       Date:  2010-11-11       Impact factor: 5.588

2.  Geriatric oncology: an overview of progresses and challenges.

Authors:  Martine Extermann
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

3.  A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status.

Authors:  W J Louwman; M J Aarts; S Houterman; F J van Lenthe; J W W Coebergh; M L G Janssen-Heijnen
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

4.  Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors.

Authors:  Gregory P Beehler; Michael Wade; Borah Kim; Lynn Steinbrenner; Laura O Wray
Journal:  J Cancer Surviv       Date:  2009-09-16       Impact factor: 4.442

5.  Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.

Authors:  Kenneth G Nepple; Andrew J Stephenson; Dorina Kallogjeri; Jeff Michalski; Robert L Grubb; Seth A Strope; Jennifer Haslag-Minoff; Jay F Piccirillo; Jay P Ciezki; Eric A Klein; Chandana A Reddy; Changhong Yu; Michael W Kattan; Adam S Kibel
Journal:  Eur Urol       Date:  2013-03-13       Impact factor: 20.096

6.  Comorbidity and survival of patients selected for radical prostatectomy at an age of 75 years or older.

Authors:  Michael Froehner; Rainer Koch; Manfred P Wirth
Journal:  Asian J Androl       Date:  2013-06-03       Impact factor: 3.285

Review 7.  Hormonal therapy in the elderly prostate cancer patient.

Authors:  Jesco Pfitzenmaier; Jens E Altwein
Journal:  Dtsch Arztebl Int       Date:  2009-04-03       Impact factor: 5.594

8.  Can patient comorbidities be included in clinical performance measures for radiation oncology?

Authors:  Jean B Owen; Najma Khalid; Alex Ho; Lisa A Kachnic; Ritsuko Komaki; May Lin Tao; Adam Currey; J Frank Wilson
Journal:  J Oncol Pract       Date:  2014-03-18       Impact factor: 3.840

9.  The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study.

Authors:  Christina G Jespersen; Mette Nørgaard; Truls E Bjerklund Johansen; Mette Søgaard; Michael Borre
Journal:  BMC Cancer       Date:  2011-12-15       Impact factor: 4.430

10.  Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis.

Authors:  Haojie Li; Elizabeth Hodgson; Louise Watson; Amit Shukla; Jeanenne J Nelson
Journal:  J Cancer Epidemiol       Date:  2012-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.